JPMorgan Downgrades Acorda Therapeutics (ACOR) to Neutral
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
JPMorgan downgraded Acorda Therapeutics (NASDAQ: ACOR) from Overweight to Neutral, price target lowered from $38 to $30.
For an analyst ratings summary and ratings history on Acorda Therapeutics click here. For more ratings news on Acorda Therapeutics click here.
Shares of Acorda Therapeutics closed at $25.42 yesterday.
For an analyst ratings summary and ratings history on Acorda Therapeutics click here. For more ratings news on Acorda Therapeutics click here.
Shares of Acorda Therapeutics closed at $25.42 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
- UBS Downgrades Converge ICT Solutions Inc (CNVRG:PM) to Neutral
- Goldman Sachs Downgrades Hysan Development Company Limited (14:HK) (HYSNY) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
